Par Drugs And Chemicals Limited (PAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Par Drugs And Chemicals Limited (PAR) has a cash flow conversion efficiency ratio of 0.146x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs115.00 Million ≈ $1.24 Million USD) by net assets (Rs785.98 Million ≈ $8.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Par Drugs And Chemicals Limited - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Par Drugs And Chemicals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Par Drugs And Chemicals Limited for a breakdown of total debt and financial obligations.
Par Drugs And Chemicals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Par Drugs And Chemicals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sarytogan Graphite Ltd
AU:SGA
|
-0.038x |
|
Lancartama Sejati Tbk
JK:TAMA
|
0.018x |
|
General Environmental Conservation Public Company Limited
BK:GENCO
|
0.006x |
|
IDT Australia Ltd
AU:IDT
|
-0.047x |
|
Globe Textiles (India) Limited
NSE:GLOBE
|
-0.089x |
|
Priceworth International Bhd
KLSE:7123
|
-0.039x |
|
Green Hydrogen Systems AS
CO:GREENH
|
-0.143x |
|
Rugby Mining Limited
V:RUG
|
1.162x |
Annual Cash Flow Conversion Efficiency for Par Drugs And Chemicals Limited (2016–2025)
The table below shows the annual cash flow conversion efficiency of Par Drugs And Chemicals Limited from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see PAR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs989.75 Million ≈ $10.70 Million |
Rs161.60 Million ≈ $1.75 Million |
0.163x | -30.95% |
| 2024-03-31 | Rs856.32 Million ≈ $9.26 Million |
Rs202.49 Million ≈ $2.19 Million |
0.236x | +25.93% |
| 2023-03-31 | Rs712.38 Million ≈ $7.70 Million |
Rs133.77 Million ≈ $1.45 Million |
0.188x | +47.65% |
| 2022-03-31 | Rs598.77 Million ≈ $6.48 Million |
Rs76.15 Million ≈ $823.55K |
0.127x | -45.05% |
| 2021-03-31 | Rs522.15 Million ≈ $5.65 Million |
Rs120.85 Million ≈ $1.31 Million |
0.231x | +22.22% |
| 2020-03-31 | Rs406.15 Million ≈ $4.39 Million |
Rs76.91 Million ≈ $831.77K |
0.189x | -27.23% |
| 2019-03-31 | Rs291.17 Million ≈ $3.15 Million |
Rs75.77 Million ≈ $819.45K |
0.260x | +24.73% |
| 2018-03-31 | Rs206.99 Million ≈ $2.24 Million |
Rs43.18 Million ≈ $467.01K |
0.209x | -56.32% |
| 2017-03-31 | Rs192.03 Million ≈ $2.08 Million |
Rs91.72 Million ≈ $991.96K |
0.478x | +27.00% |
| 2016-03-31 | Rs173.56 Million ≈ $1.88 Million |
Rs65.27 Million ≈ $705.91K |
0.376x | -- |
About Par Drugs And Chemicals Limited
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, m… Read more